Browsing Tag
Haisco Pharmaceutical Group
2 posts
Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes
Nuvectis Pharma gains ciprocopan validation in China, but licensing costs, dilution and ex-China execution will determine its real value.
Nuvectis Pharma just raised $100 million, so why are NVCT shareholders selling?
Nuvectis Pharma shares fell 19% after a $100 million offering priced at $20. Read what dilution, runway and pipeline expansion mean for NVCT investors now!